REZDIFFRA (resmetirom) by Madrigal Pharmaceuticals is thyroid hormone receptor beta agonists [moa]. Approved for non-alcoholic fatty liver disease, metabolic dysfunction-associated steatohepatitis. First approved in 2024.
Drug data last refreshed 22h ago
Thyroid Hormone Receptor beta Agonists
Thyroid Hormone Receptor beta Agonist
Worked on REZDIFFRA at Madrigal Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Rezdiffra Pregnancy and Lactation Registry
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moMadrigal Pharmaceuticals is hiring 10 roles related to this product